Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908799 · ClinicalTrials.gov registry record
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
A clinical trial, sponsored by Aetion.
- Completed
- Registry status
- 1,854
- Enrollment target
NCT05908799: Completed study, sponsored by Aetion.
NCT05908799 is a clinical trial that has completed, run by Aetion. The registered enrollment target is 1,854 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05908799 has completed, sponsored by Aetion.
- COMPLETED
- Registry status
- 1,854 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base supporting the utility of real-world data through the emulation of randomized controlled trials in the oncology setting. The purpose of this work is to demonstrate whether real-world evidence studies can provide reliable conclusions on treatment effectiveness to inform further applications of real-world data in pharmaceutical product label expansion, post-marketing safety, and other purposes that are complementary to RCTs.
Primary Outcome
Relative hazard of mortality due to any cause
Interventions
- DRUG Pembrolizumab + Pemetrexed-Platinum
- DRUG Pemetrexed-Platinum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,854 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2023-08-31 |
What the finished NCT05908799 record still lists
NCT05908799 is an observational study that tracks outcomes without assigning an intervention. Its 1,854 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab + Pemetrexed-Platinum is the first listed.
NCT05908799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05908799 about?
NCT05908799 is a clinical study titled "Emulation of the KEYNOTE-189 Trial Using Electronic Health Records". Investigators are building an empirical evidence base supporting the utility of real-world data through the emulation of randomized controlled trials in the oncology setting. The purpose of this work is to demonstrate whether real-world evidence studies can provide reliable conclusions on treatment ...
What is the current status of trial NCT05908799?
This trial is currently completed. The enrollment target is 1,854 participants. The study started on 2023-06-05. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05908799?
The interventions under investigation include: Pembrolizumab + Pemetrexed-Platinum (DRUG), Pemetrexed-Platinum (DRUG).
Who is sponsoring clinical trial NCT05908799?
This trial is sponsored by Aetion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI